Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market

• Hong Kong-listed Insilico Medicine has reached a deal with U.S. pharma giant Eli Lilly for AI-discovered drugs.
• The two companies have worked together since 2023.
• Insilico’s CEO, Alex Zhavoronkov, said Eli Lilly has a competitive edge in certain aspects of AI.

Source: https://www.cnbc.com/2026/03/29/eli-lilly-reaches-deal-to-bring-ai-developed-drugs-to-global-market.html